| Autor: |
Anker, S.D. Butler, J. Filippatos, G. Shahzeb Khan, M. Ferreira, J.P. Bocchi, E. Böhm, M. Brunner-La Rocca, H.P. Choi, D.-J. Chopra, V. Chuquiure, E. Giannetti, N. Gomez-Mesa, J.E. Janssens, S. Januzzi, J.L. Gonzalez-Juanatey, J.R. Merkely, B. Nicholls, S.J. Perrone, S.V. Piña, I.L. Ponikowski, P. Senni, M. Seronde, M.-F. Sim, D. Spinar, J. Squire, I. Taddei, S. Tsutsui, H. Verma, S. Vinereanu, D. Zhang, J. Jamal, W. Schnaidt, S. Schnee, J.M. Brueckmann, M. Pocock, S.J. Zannad, F. Packer, M. EMPEROR-Preserved Trial Committees Investigators |
| Jazyk: |
angličtina |
| Rok vydání: |
2020 |
| Popis: |
Aims: EMPEROR-Preserved is an ongoing trial evaluating the effect of empagliflozin in patients with heart failure with preserved ejection fraction (HFpEF). This report describes the baseline characteristics of the EMPEROR-Preserved cohort and compares them with patients enrolled in prior HFpEF trials. Methods and results: EMPEROR-Preserved is a phase III randomized, international, double-blind, parallel-group, placebo-controlled trial in which 5988 symptomatic HFpEF patients [left ventricular ejection fraction (LVEF) >40%] with and without type 2 diabetes mellitus (T2DM) have been enrolled. Patients were required to have elevated N-terminal pro B-type. natriuretic peptide (NT-proBNP) concentrations (i.e. >300 pg/mL in patients without and >900 pg/mL in patients with atrial fibrillation) along with evidence of structural changes in the heart or documented history of heart failure hospitalization. Among patients enrolled from various regions (45% Europe, 11% Asia, 25% Latin America, 12% North America), the mean age was 72 ± 9 years, 45% were women. Almost all patients had New York Heart Association class II or III symptoms (99.6%), and 23% had prior heart failure hospitalization within 12 months. Thirty-three percent of the patients had baseline LVEF of 41–50%. The mean LVEF (54 ± 9%) was slightly lower while the median NT-proBNP [974 (499–1731) pg/mL] was higher compared with previous HFpEF trials. Presence of comorbidities such as diabetes (49%) and chronic kidney disease (50%) were common. The majority of the patients were on angiotensin-converting enzyme inhibitors/angiotensin receptor blockers/angiotensin receptor–neprilysin inhibitors (80%) and beta-blockers (86%), and 37% of patients were on mineralocorticoid receptor antagonists. Conclusion: When compared with prior trials in HFpEF, the EMPEROR-Preserved cohort has a somewhat higher burden of comorbidities, lower LVEF, higher median NT-proBNP and greater use of mineralocorticoid receptor antagonists at baseline. Results of the EMPEROR-Preserved trial will be available in 2021. © 2020 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
